|
1
|
Ostrom QT, Gittleman H, Farah P, Ondracek
A, Chen Y, Wolinsky Y, Stroup NE, Kruchko C and Barnholtz-Sloan JS:
CBTRUS statistical report: Primary brain and central nervous system
tumors diagnosed in the United States in 2006–2010. Neuro Oncol. 15
Suppl 2:ii1–ii56. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al European Organisation for Research and Treatment
of Cancer Brain Tumour and Radiation Oncology Groups; National
Cancer Institute of Canada Clinical Trials Group. Effects of
radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised
phase III study, : 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nakagawa K, Aoki Y, Fujimaki T, Tago M,
Terahara A, Karasawa K, Sakata K, Sasaki Y, Matsutani M and Akanuma
A: High-dose conformal radiotherapy influenced the pattern of
failure but did not improve survival in glioblastoma multiforme.
Int J Radiat Oncol Biol Phys. 40:1141–1149. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kohler N and Lipton A: Platelets as a
source of fibroblast growth-promoting activity. Exp Cell Res.
87:297–301. 1974. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ross R, Glomset J, Kariya B and Harker L:
A platelet-dependent serum factor that stimulates the proliferation
of arterial smooth muscle cells in vitro. Proc Natl Acad Sci USA.
71:pp. 1207–1210. 1974; View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Heldin CH, Westermark B and Wasteson A:
Platelet-derived growth factor: Purification and partial
characterization. Proc Natl Acad Sci USA. 76:pp. 3722–3726. 1979;
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hermansson M, Nistér M, Betsholtz C,
Heldin CH, Westermark B and Funa K: Endothelial cell hyperplasia in
human glioblastoma: Coexpression of mRNA for platelet-derived
growth factor (PDGF) B chain and PDGF receptor suggests autocrine
growth stimulation. Proc Natl Acad Sci USA. 85:pp. 7748–7752. 1988;
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Maxwell M, Naber SP, Wolfe HJ,
Galanopoulos T, Hedley-Whyte ET, Black PM and Antoniades HN:
Coexpression of platelet-derived growth factor (PDGF) and
PDGF-receptor genes by primary human astrocytomas may contribute to
their development and maintenance. J Clin Invest. 86:131–140. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Plate KH, Breier G, Farrell CL and Risau
W: Platelet-derived growth factor receptor-beta is induced during
tumor development and upregulated during tumor progression in
endothelial cells in human gliomas. Lab Invest. 67:529–534.
1992.PubMed/NCBI
|
|
11
|
Chen D, Li Y, Mei Y, Geng W, Yang J, Hong
Q, Feng Z, Cai G, Zhu H, Shi S, et al: miR-34a regulates mesangial
cell proliferation via the PDGFR-β/Ras-MAPK signaling pathway. Cell
Mol Life Sci. 71:4027–4042. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nazarenko I, Hede SM, He X, Hedrén A,
Thompson J, Lindström MS and Nistér M: PDGF and PDGF receptors in
glioma. Ups J Med Sci. 117:99–112. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ren H, Tan X, Dong Y, Giese A, Chou TC,
Rainov N and Yang B: Differential effect of imatinib and synergism
of combination treatment with chemotherapeutic agents in malignant
glioma cells. Basic Clin Pharmacol Toxicol. 104:241–252. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Russell JS, Brady K, Burgan WE, Cerra MA,
Oswald KA, Camphausen K and Tofilon PJ: Gleevec-mediated inhibition
of Rad51 expression and enhancement of tumor cell radiosensitivity.
Cancer Res. 63:7377–7383. 2003.PubMed/NCBI
|
|
15
|
Holdhoff M, Kreuzer KA, Appelt C, Scholz
R, Na IK, Hildebrandt B, Riess H, Jordan A, Schmidt CA, van Etten
RA, et al: Imatinib mesylate radiosensitizes human glioblastoma
cells through inhibition of platelet-derived growth factor
receptor. Blood Cells Mol Dis. 34:181–185. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ranza E, Bertolotti A, Facoetti A,
Mariotti L, Pasi F, Ottolenghi A and Nano R: Influence of imatinib
mesylate on radiosensitivity of astrocytoma cells. Anticancer Res.
29:4575–4578. 2009.PubMed/NCBI
|
|
17
|
Savage DG and Antman KH: Imatinib
mesylate-a new oral targeted therapy. N Engl J Med. 346:683–693.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen SW, Zhang XR, Wang CZ, Chen WZ, Xie
WF and Chen YX: RNA interference targeting the platelet-derived
growth factor receptor beta subunit ameliorates experimental
hepatic fibrosis in rats. Liver Int. 2008. View Article : Google Scholar
|
|
19
|
Reardon DA, Desjardins A, Vredenburgh JJ,
Herndon JE II, Coan A, Gururangan S, Peters KB, McLendon R,
Sathornsumetee S, Rich JN, et al: Phase II study of Gleevec plus
hydroxyurea in adults with progressive or recurrent low-grade
glioma. Cancer. 118:4759–67. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Biade S, Stobbe CC and Chapman JD: The
intrinsic radiosensitivity of some human tumor cells throughout
their cell cycles. Radiat Res. 147:416–421. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen H, Huang Q, Dong J, Zhai DZ, Wang AD
and Lan Q: Overexpression of CDC2/CyclinB1 in gliomas, and CDC2
depletion inhibits proliferation of human glioma cells in vitro and
in vivo. BMC Cancer. 8:292008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
He J, Li J, Ye C, Zhou L, Zhu J, Wang J,
Mizota A, Furusawa Y and Zhou G: Cell cycle suspension: A novel
process lurking in G2 arrest. Cell Cycle. 10:1468–1476. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Maity A, Hwang A, Janss A, Phillips P,
McKenna WG and Muschel RJ: Delayed cyclin B1 expression during the
G2 arrest following DNA damage. Oncogene. 13:1647–1657.
1996.PubMed/NCBI
|
|
24
|
Silva MF, Khokhar AR, Qureshi MZ and
Farooqi AA: Ionizing radiations induce apoptosis in TRAIL resistant
cancer cells: in vivo and in vitro analysis. Asian Pac J Cancer
Prev. 15:1905–1907. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Takano S, Ishikawa E, Sakamoto N, Matsuda
M, Akutsu H, Noguchi M, Kato Y, Yamamoto T and Matsumura A:
Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute
molecular genetic testing and predict patient prognosis in grade
III adult diffuse gliomas. Brain Tumor Pathol. 33:107–116. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lafuente JV, Adán B, Alkiza K, Garibi JM,
Rossi M and Cruz-Sánchez FF: Expression of vascular endothelial
growth factor (VEGF) and platelet-derived growth factor
receptor-beta (PDGFR-beta) in human gliomas. J Mol Neurosci.
13:177–185. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fenton BM, Paoni SF and Ding I:
Pathophysiological effects of vascular endothelial growth factor
receptor-2-blocking antibody plus fractionated radiotherapy on
murine mammary tumors. Cancer Res. 64:5712–5719. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shannon AM and Williams KJ:
Antiangiogenics and radiotherapy. J Pharm Pharmacol. 60:1029–1036.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jain RK: Normalization of tumor
vasculature: An emerging concept in antiangiogenic therapy.
Science. 307:58–62. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cohen-Jonathan Moyal E: Angiogenic
inhibitors and radiotherapy: From the concept to the clinical
trial. Cancer Radiother. 13:562–567. 2009.(In French). PubMed/NCBI
|
|
31
|
Raymond E: PDGFR inhibition in brain
tumours-oft expectation fails where most it promises. Eur J Cancer.
45:2236–2238. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gorski DH, Beckett MA, Jaskowiak NT,
Calvin DP, Mauceri HJ, Salloum RM, Seetharam S, Koons A, Hari DM,
Kufe DW and Weichselbaum RR: Blockage of the vascular endothelial
growth factor stress response increases the antitumor effects of
ionizing radiation. Cancer Res. 59:3374–3378. 1999.PubMed/NCBI
|
|
33
|
Omuro AM: Exploring multi-targeting
strategies for the treatment of gliomas. Curr Opin Investig Drugs.
9:1287–1295. 2008.PubMed/NCBI
|
